U.S., April 21 -- ClinicalTrials.gov registry received information related to the study (NCT07540403) titled 'Survival Analysis in patiEnts With Bad Prognosis Epithelial Ovarian CArcinoma' on March 13, 2025.
Brief Summary: Ovarian carcinoma is the most lethal gynecological malignancy. Epithelial ovarian carcinoma is the gynecological malignancy with the highest mortality rate. The prognosis of patients with recurrent disease is highly heterogeneous and is typically poor in cases of ovarian carcinoma with a progression-free survival (PFS) ≤ 6 months, for which therapeutic options are limited. However, it has been shown that patients with a PFS ≤ 6 months may not respond effectively to further treatments, whereas, conversely, pat...